<DOC>
	<DOCNO>NCT00738907</DOCNO>
	<brief_summary>We hypothesize quantitative measurement beta cell mass within endocrine pancreas obtain PET via target vesicular monoamine type 2 transporter radioligand [ 11C ] DTBZ . significant difference [ 11C ] DTBZ uptake anatomical space pancreas normal individual BCM predict great less normal base measurement insulin secretion .</brief_summary>
	<brief_title>Assessment Beta Cell Mass PET Scans With 11C Dihydrotetrabenazine ( DTBZ ) Longstanding Type 1 Diabetes .</brief_title>
	<detailed_description>Diabetes result insulin secretory capacity beta cell population lose severely compromise . Plasma insulin level use surrogate marker beta cell mass ( BCM ) insulin level often correlate well BCM `` gold standard measurement '' obtain type information would great value . The aim propose study evaluate islet image technique use PET scan able use directly measure BCM thus provide valuable information monitoring disease progress response therapy people diabetes people high risk diabetes . Type 1 diabetes ( T1DM ) occur beta cell selectively destroy T cell mediate autoimmune process . People high risk develop T1DM , first degree relative patient T1DM , sometimes identified disease develop measure autoantibody beta cell , however test neither sensitive specific . In contrast , type 2 diabetes ( T2DM ) occur set insulin resistance lead hyperinsulinemia . In people high risk T2DM , beta cell mass increase meet demand insulin . The individual become diabetic BCM insulin production longer compensate increase need insulin , blood glucose begin rise . Loss BCM may occur T2DM advance . People high risk T2DM include first degree relative patient T2DM obesity , insulin resistance metabolic syndrome . Little known natural history BCM , turnover cell lifetime , course inflammation diabetes . This principally pancreas highly heterogeneous organ difficult biopsy without significant complication , BCM 1-2 % organ . Accurate assessment BCM human diabetes limited autopsy study , usually suffer inadequate clinical information; thus , development noninvasive mean BCM measurement could important , intervention therapy T1DM T2DM , islet regeneration/stem cell therapy islet transplantation . Until recently , islet cell mass visualization clinically feasible . We previously identify specific marker pancreatic beta cell call vesicular monoamine transporter type 2 ( VMAT2 ) . In preclinical study , show image beta cell mass PET scan use radioligand feasible rat dosimetry study conduct baboon . This radioligand , [ 11C ] DTBZ , use previously human subject clinical trial evaluate P.E.T scan brain patient bipolar illness schizophrenia compare healthy control subject . In current protocol , propose use radioligand , [ 11C ] DTBZ , bind VMAT2 positron emission tomography ( PET ) scan assess whether PET measure beta cell mass human subject .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Potential participant must meet follow inclusion criterion : 1 . Informed consent obtain participant 2 . Age 18 45 year 3 . Healthy nondiabetic subject normal fast blood sugar ( &lt; 100 mg/dl ) , BMI 18.5 24.9 , history type 2 diabetes first degree relative 4 . Type 1 diabetes define : ADA criterion judgment physician; diabetes onset young age 18 , duration &gt; 5 year , BMI 18.5 24.9 . Insulin dose &lt; 0.8 units/kg/day . Fasting cpeptide &lt; 0.1 ng/ml 5 . Obese hyperinsulinemic subject BMI &gt; 30 fast insulin &gt; 20 cpeptide &gt; 4.6 ng/ml normal fast blood sugar &lt; 100 mg/dl . 6 . Able tolerate PET imaging : claustrophobic , able lie supine 1.5 hour 7 . Normal liver renal function test include normal spot urine microalbumin/creatinine; normal complete blood count ( CBC ) include hematocrit &gt; 31.8 % woman , &gt; 36.7 % men , white blood cell count ( WBC ) &gt; 3.4 K/mm3 platelet count &gt; 162 K/mm3 8 . Adequate collateral circulation wrist assess Allen Test . Potential participant must follow exclusion criterion : 1 . Previous current treatment drug influence beta cell function insulin sensitivity ( e.g . oral hypoglycemic agent , glucocorticoid ) ; antipsychotic , antianxiety , antidepressant medication ( eg monoamine oxidase ( MAO ) inhibitor , 5HT inhibitor , tricyclic antidepressant ) ; treatment reserpine; treatment beta2receptor agonist ( eg , terbutaline ) ; treatment anticoagulant medication . 2 . History movement disorder Parkinson 's Disease Huntington 's Disease 3 . History psychiatric illness depression , bipolar disease , anxiety schizophrenia . 4 . If female childbearing age , currently pregnant , breastfeed use form birth control 5 . Previous current use cocaine , methamphetamine , ecstasy ( 3,4 methylenedioxymethamphetamine ( MDMA ) ) 6 . Current daily intake caffeine &gt; 500 mg/day ( &gt; 45 cup coffee; &gt; 10 12oz can soda ) 7 . Current history cigarette smoke 8 . Consumption 1 alcoholic drink per day 9 . Evidence chronic infection 10 . History malignancy 11 . Any prior participation research protocol within past year involve radiation , exception plain radiography study ( i.e. , chest xrays ) . 12 . Medical implant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Type 1 diabetes</keyword>
</DOC>